Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI106279

Metabolic properties of IgG subclasses in man

Andreas Morell, William D. Terry, and Thomas A. Waldmann

1Immunology Branch, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Morell, A. in: PubMed | Google Scholar

1Immunology Branch, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Terry, W. in: PubMed | Google Scholar

1Immunology Branch, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Waldmann, T. in: PubMed | Google Scholar

Published April 1, 1970 - More info

Published in Volume 49, Issue 4 on April 1, 1970
J Clin Invest. 1970;49(4):673–680. https://doi.org/10.1172/JCI106279.
© 1970 The American Society for Clinical Investigation
Published April 1, 1970 - Version history
View PDF
Abstract

Metabolic properties of the four subclasses of human IgG were investigated by performing 47 turnover studies in individuals with normal IgG serum concentrations, as well as in patients with an increased level of one of the subclasses. Studies in 12 subjects with normal IgG serum concentration showed that the average biologic half-life of G1, G2, and G4 was 21 days, while that of G3 was only 7.1 days. Fractional catabolic rates of G1, G2, and G4 were 6.9 to 8% of the intravascular pool per day. G3, however, had a higher fractional catabolic rate, amounting to 16.8% of the intravascular pool per day. Distribution of the subclasses was such that the intravascular compartment contained 51-54% of the total body pools of G1, G2, and G4, but 64% of the total body pool of G3.

The short survival and high fractional catabolic rate of G3 is an inherent property of these molecules, and is not due to denaturation during isolation and radiolabeling. This was demonstrated by studies of a patient with a serum G3-myeloma protein. The survival of her own protein, separately labeled either in vivo with guanidoarginine-14C or in vitro with 125I, was determined in the patient. Survivals of the in vivo and in vitro labeled proteins were identical.

G1 and G3 serum concentrations and synthetic rates were determined. The mean serum concentration of G1 was 6.8 mg/ml and that of G3 was 0.7 mg/ml, while their synthetic rates were 25.4 and 3.4 mg/kg per day respectively. The low serum concentration of IgG2 thus results from a combination of high catabolic and low synthetic rates.

Studies in 10 patients with multiple myeloma showed that an elevated serum concentration of any IgG subclass was associated with shortened biologic half-life and increased fractional catabolic rate of all subclasses. The implications of this concentration-catabolism relationship are discussed. The serum concentration of nonmyeloma IgG was usually low in myeloma patients and the synthesis of nonmyeloma IgG was somewhat decreased, suggesting that low serum concentrations of nonmyeloma IgG result from decreased synthesis, as well as from an increased fractional catabolic rate.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 673
page 673
icon of scanned page 674
page 674
icon of scanned page 675
page 675
icon of scanned page 676
page 676
icon of scanned page 677
page 677
icon of scanned page 678
page 678
icon of scanned page 679
page 679
icon of scanned page 680
page 680
Version history
  • Version 1 (April 1, 1970): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts